Architect or Destroyer: The Diversity of Glucocorticoid Receptor Signaling Pathways in the Brain

Glucocorticoids (GCs), acting through the glucocorticoid (GR) and mineralocorticoid (MR) receptors, are essential for brain development, stress adaptation, and metabolic homeostasis, yet their signaling exhibits context-dependent diversity yielding either beneficial or detrimental outcomes. This review synthesizes current knowledge on the multifaceted mechanisms through which GR integrates hormonal, metabolic, and stress signals to modulate transcriptional programs in the brain. We highlight three key levels of GR regulatory complexity: the diversity of DNA GR-binding motifs, GR-mediated epigenetic remodeling, and rapid non-genomic cascades. Clinical and experimental data reveal that while physiological GC levels are critical for normal maturation and function, excess or chronic exposure, especially during sensitive developmental windows, can disrupt neurogenesis, synaptogenesis, and myelination, predisposing individuals to cognitive, affective, and neurodegenerative disorders. We discuss promising therapeutic strategies based on selective modulation of MR/GR balance, interference with specific co-regulatory complexes, and targeted manipulation of DNMT/TET/HDAC cascades. Unlike most existing reviews—which address either (a) the MR–GR interaction as a whole receptor system, (b) non-genomic effects in isolation from genomic ones, or (c) the clinical manifestations of stress-associated disorders without an in-depth mechanistic analysis of GR targets—our manuscript attempts to integrate these three levels of GR regulation into a unified hierarchical system (binding motifs → epigenetic remodeling → the conditional nature of the boundary between genomic and non-genomic GR effects). We aim to explicitly demonstrate how these levels jointly determine cell-specific outcomes, rather than describing them in parallel as independent mechanisms. However, critical gaps remain in understanding the precise assembly of GR-co-regulator complexes in defined neuronal and glial populations, as well as the feasibility of selectively engaging beneficial GR signaling branches without systemic suppression of the hypothalamic–pituitary–adrenal axis. Addressing these questions is essential for developing next-generation therapies that harness GR’s architectural potential while avoiding its adverse or unwanted consequences.